SHR0302 is yet another selective JAK1 inhibitor that is in early phase clinical trials for a variety of indications, including CD (NCT03677648), RA (NCT02892370, NCT02665910, NCT02423538), AS (NCT04481139) and AA (NCT04346316). This evidence concerns the gene JAK1 and rheumatoid arthritis.